pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
Parabilis Medicines · news · pharmadog
← back to Parabilis Medicines
News mentioning Parabilis Medicines
36
stories
10d
ADARx raises $446M in biotech’s third largest IPO of 2026, City files to go public
biospace
13d
Iambic maintains momentum from string of Big Pharma partnerships by aiming for IPO
fiercebiotech
14d
Retension and Lilly-backed TRex Bio both set out plans to join biotech IPO stampede
fiercebiotech
17d
Inflammation biotech Electra charges up with $350M from upsized IPO
fiercebiotech
21d
Electra aims for $342M IPO to power inflammatory drug’s push through phase 3
fiercebiotech
27d
BrainChild Bio targets deadly pediatric brain cancer with $116M series A
biospace
29d
AbbVie-backed ADARx plans IPO to bankroll array of clinical-stage siRNA therapies
fiercebiotech
Aug 26, 26
JATT mastermind launches latest biotech-focused SPAC via $60M IPO
fiercebiotech
Aug 25, 26
Biotech IPOs approach ‘escape velocity’ barring yellow flags that could threaten rebound
biospace
Aug 25, 26
Young startups miss out on biotech venture funding rebound, MassBio says
biopharma dive
Aug 20, 26
Scribe’s early-stage IPO standout defies biotech’s derisking trend
biospace
Aug 18, 26
Regeneron ends eye disease study due to antibody's safety profile
biospace
Aug 18, 26
Regeneron ends eye disease study due to antibody's safety profile
biospace
Aug 12, 26
With tech backing, AI biotechs force biopharma into ‘fail-fast’ drug development
biospace
Aug 7, 26
2026 Q2 Job Market Report: Job postings keep rising as fewer companies cut employees
biospace
Aug 7, 26
BlossomHill, Latigo outshine IPO expectations with oversubscribed debuts
fiercebiotech
Aug 6, 26
With $263M, LifeMine unearths a new drug for organ transplants
biopharma dive
Aug 6, 26
Braveheart charges past expectations with $382.5M IPO to fund cardio drug from Hengrui
fiercebiotech
Aug 5, 26
‘Greg, you’ve got to bring back this platform’: How LifeMine won over Gates and Bezos for $188M series E
fiercebiotech
Jul 31, 26
Apnimed’s IPO dream comes true with upsized $192M IPO to fund sleep apnea pill launch
fiercebiotech
Jul 24, 26
Scribe reels in nearly $129M in rare early-stage IPO for a gene editing biotech
biospace
Jul 24, 26
Scribe secures $129M in a rare gene editing IPO
biopharma dive
Jul 24, 26
Scribe records upsized $129M IPO to bankroll lipid-lowering genetic meds
fiercebiotech
Jul 20, 26
Scribe aims for $96M IPO to fund clinical push for lipid-lowering genetic meds
fiercebiotech
Jul 19, 26
Latigo preps IPO to fund non-opioid pain drug rival to Vertex’s Journax
fiercebiotech
Jul 19, 26
Geopolitics ‘chills’ British biotech IPO plans, despite $2B in Q2 VC funds
fiercebiotech
Jul 16, 26
Braveheart, Attovia, Vogenx keep IPOs ballooning with plans to compete in cardiometabolic, immuno
biospace
Jul 13, 26
Biotech startup funding gap widens despite rebound in VC investment
biopharma dive
Jun 11, 26
Kardigan plans $320M IPO for heart drugs as Nasdaq listings gain steam
endpoints
Jun 10, 26
Parabilis CEO Mathai Mammen on biotech's record IPO
endpoints
← prev
page 1 of 2
next →
